Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:17 AM
Ignite Modification Date:
2025-12-25 @ 1:17 AM
NCT ID:
NCT06360393
Eligibility Criteria:
Inclusion Criteria:
* Age ≥ 18 years.
* Confirmed asthma diagnoses (≥12% and \>200 ml reversibility in FEV1 or positive histamine/methacholine provocation test or FeNO ≥50) according to the asthma guidelines
* Diagnosed with severe, refractory asthma with eligibility for treatment with specific asthma biologics (omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab)
* Using medium or high ICS + LABA +/- LAMA+/-SABA) by pMDI+spacer
* Willing to sign informed consent
Exclusion Criteria:
* The use of the Symbicort Aerosol or the Trixeo Aerosphere in combination with a spacer (these inhalers are not compatible with the smart spacer)
* Inability to sufficiently understand and read the Dutch language
* Current pregnancy
* Currently terminally ill
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06360393
Study Brief:
Protocol Section:
NCT06360393